Waldencast (WALD) Hisse Özeti
Waldencast plc, Amerika Birleşik Devletleri, Kanada, Avrupa, Orta Doğu, Hindistan, Avustralya ve Yeni Zelanda'da güzellik ve sağlıklı yaşam sektöründe faaliyet göstermektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 2/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 0/6 |
| Finansal Sağlık | 4/6 |
| Temettüler | 0/6 |
WALD Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Waldencast plc Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$1.72 |
| 52 Haftanın En Yüksek Seviyesi | US$3.22 |
| 52 Haftanın En Düşük Seviyesi | US$0.72 |
| Beta | -0.042 |
| 1 Aylık Değişim | 0% |
| 3 Aylık Değişim | 56.36% |
| 1 Yıllık Değişim | -35.58% |
| 3 Yıllık Değişim | -75.71% |
| 5 Yıllık Değişim | n/a |
| Halka arzdan bu yana değişim | -77.69% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 29
WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound
The analyst price target for Waldencast has been raised from $1.87 to $2.28, with analysts pointing to the announced sale of the Obagi skin care and aesthetics business for up to $460 million as a key factor supporting the higher valuation. What’s in the News for Waldencast Waldencast announced that the U.S. Food and Drug Administration approved Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio and targeting cheek augmentation and midface contour correction for patients over 21.
Anlatı Güncellemesi • Jun 15
WALD: Obagi Sale And Injectables Launch Will Support Future Upside
Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.
Anlatı Güncellemesi • Jun 01
WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs
Narrative Update on Waldencast Analysts have lowered their average price targets on Waldencast by about $1 to a range around $2 to $2.50, citing recent EBITDA and sales misses, ongoing costs tied to regulatory and review processes, and what they describe as slower recent growth. At the same time, they continue to point to the perceived strength of the Obagi and Milk brands, as well as potential from the Saypha injectables launch.Recent updates
Anlatı Güncellemesi • Jun 29
WALD: Obagi Sale And Injectables Expansion Will Support Future Share Rebound
The analyst price target for Waldencast has been raised from $1.87 to $2.28, with analysts pointing to the announced sale of the Obagi skin care and aesthetics business for up to $460 million as a key factor supporting the higher valuation. What’s in the News for Waldencast Waldencast announced that the U.S. Food and Drug Administration approved Obagi saypha ChIQ injectable hyaluronic acid gel, expanding the Obagi Medical injectable portfolio and targeting cheek augmentation and midface contour correction for patients over 21.Anlatı Güncellemesi • Jun 15
WALD: Obagi Sale And Injectables Launch Will Support Future Upside
Analysts have lifted their price target on Waldencast stock to $3.00 from $2.50, citing the agreed sale of the Obagi skin care and aesthetics business for up to $460m and the view that current valuation does not fully reflect the strength of Obagi, Milk and the upcoming Saypha injectables launch. Analyst Commentary Bullish analysts see the agreed sale of the Obagi skin care and aesthetics business and the ongoing investment in Saypha injectables as key supports for the recent reset to a $3.00 price target.Anlatı Güncellemesi • Jun 01
WALD: Brand Strength And Injectables Expansion Will Drive Future Repricing Despite Higher Costs
Narrative Update on Waldencast Analysts have lowered their average price targets on Waldencast by about $1 to a range around $2 to $2.50, citing recent EBITDA and sales misses, ongoing costs tied to regulatory and review processes, and what they describe as slower recent growth. At the same time, they continue to point to the perceived strength of the Obagi and Milk brands, as well as potential from the Saypha injectables launch.Anlatı Güncellemesi • May 04
WALD: Brand Strength And Injectables Launch Will Support Future Share Rebound
Analysts have trimmed their average price target on Waldencast from about $3.08 to roughly $1.87, reflecting recent EBITDA and sales shortfalls, slower growth and higher costs. At the same time, they point to ongoing brand strength and potential upside from the Saypha injectables launch.Anlatı Güncellemesi • Apr 20
WALD: Brand Strength And Injectables Rollout Will Support Future Repricing
Analysts have trimmed their average price target for Waldencast to a range of $2.00 to $2.50, reflecting recent EBITDA and sales shortfalls, higher ongoing review and investigation costs, and more moderate revenue growth assumptions. They continue to highlight the strength of the Obagi and Milk brands, as well as potential upside from the Saypha injectables launch.Anlatı Güncellemesi • Apr 05
WALD: Brand Equity And Aesthetics Partnerships Will Support Future Upside
Analysts have trimmed their average price targets for Waldencast to a range of about $2 to $2.50 from prior levels near $3 to $4, citing recent EBITDA and sales misses, ongoing SEC and review related costs, and the view that the brands still have room to grow despite a transition period. Analyst Commentary Recent research updates show that while targets have been reduced, several bullish analysts still view Waldencast as an early stage, brand driven story in a transition phase.Anlatı Güncellemesi • Mar 22
WALD: Aesthetics Partnerships And Brand Strength Will Support Future Upside
Analysts have trimmed their average price target on Waldencast to $2.50, down from $4.00, reflecting recent earnings misses, ongoing investment in the Saypha injectables launch, slower-than-expected growth and higher costs tied to regulatory and review processes, even as they continue to highlight the strength of the Obagi and Milk brands. Analyst Commentary Bullish analysts are cutting their price targets on Waldencast, but several still point to what they see as underappreciated assets and future product catalysts.Anlatı Güncellemesi • Mar 07
WALD: Jefferies Buy Rating And Aesthetics Partnerships Will Support $4 Upside
Analysts have raised their blended price target for Waldencast to $4.00, citing updated assumptions that include a lower discount rate, an adjusted profit margin outlook, and a higher future P/E multiple, as well as support from recent Street research. Analyst Commentary Street research around Waldencast has tilted constructive, with bullish analysts pointing to a clearer earnings path and a more supportive valuation framework behind the updated US$4.00 blended price target.Anlatı Güncellemesi • Feb 21
WALD: Future Margin Recovery And Distribution Gains Will Support Share Rebound
Analysts have held Waldencast's price target at $3.00, with the latest updates reflecting lower assumed profit margins and a higher future P/E multiple, while incorporating mixed recent research that includes a Buy initiation and a prior downgrade after "disappointing" Q2 results and a reduced FY25 outlook. Analyst Commentary Recent commentary around Waldencast reflects a split view, with some focusing on long term brand potential and others zeroing in on execution hiccups and trimmed outlooks.Anlatı Güncellemesi • Feb 06
WALD: Future Retail Distribution Gains Will Support Recovery After Earnings Setbacks
Narrative Update on Waldencast The analyst price target for Waldencast has been revised slightly lower to about $3.08 from about $3.20, as analysts balance a higher discount rate and a lower assumed future P/E with generally supportive views following the recent Jefferies initiation, along with concerns highlighted after Telsey's reaction to "disappointing" Q2 results and the reduced FY25 outlook. Analyst Commentary Recent research on Waldencast reflects a mix of optimism around the long term brand opportunity and caution around execution and near term earnings delivery.Anlatı Güncellemesi • Jan 23
WALD: Expanded Beauty Distribution Will Support $4 Upside After Mixed Research
Analysts have trimmed their price target on Waldencast to $4.00, reflecting a slightly higher discount rate and modest adjustments to growth and P/E assumptions following mixed recent research, including a downgrade after "disappointing" Q2 results and an assumed rating elsewhere. Analyst Commentary Recent research on Waldencast sends a mixed signal, with one firm trimming its stance after Q2 and another assuming coverage with a more constructive view.Analiz Makalesi • Jan 10
Waldencast plc's (NASDAQ:WALD) Stock Retreats 30% But Revenues Haven't Escaped The Attention Of Investors
Waldencast plc ( NASDAQ:WALD ) shareholders won't be pleased to see that the share price has had a very rough month...Anlatı Güncellemesi • Jan 07
WALD: Expanded Beauty Distribution Will Support Recovery After Recent Guidance Reset
Analysts now hold Waldencast's fair value steady at about US$4.00 per share, with a US$3.00 price target that reflects caution after what they describe as disappointing Q2 results, reduced FY25 guidance, and sales pressure at the Milk brand despite broader distribution gains. Analyst Commentary Even with the recent downgrade and cautious stance on near term execution, some commentary still points to potential upside drivers that investors are watching closely.Anlatı Güncellemesi • Dec 14
WALD: Expanded Beauty Distribution Will Drive Rebound After Recent Earnings Reset
Analysts have trimmed their price target on Waldencast to about $4 from roughly $5, citing weaker than expected Q2 results, a lowered FY25 outlook, and slower growth at key brand Milk despite new distribution gains. Analyst Commentary Bullish analysts acknowledge that recent results and guidance have pressured near term expectations, but they continue to see upside potential for Waldencast as execution improves and the growth algorithm normalizes.Anlatı Güncellemesi • Nov 28
WALD: Future Retail Partnerships Will Drive Recovery After Recent Setbacks
Analysts have revised Waldencast's price target downward from $3.50 to $3.20, citing weaker than expected quarterly results and ongoing challenges impacting sales growth and profitability. Analyst Commentary Bullish Takeaways Despite near-term headwinds, Waldencast continues to increase its distribution footprint.Analiz Makalesi • Nov 26
Waldencast (NASDAQ:WALD) Is Carrying A Fair Bit Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • Nov 26
Revenues Tell The Story For Waldencast plc (NASDAQ:WALD) As Its Stock Soars 33%
Waldencast plc ( NASDAQ:WALD ) shares have continued their recent momentum with a 33% gain in the last month alone. Not...Seeking Alpha • Sep 23
Waldencast: Fairly Valued With Ulta Lift Already Reflected, Saypha Deal Adds Optionality
Summary Waldencast faces ongoing challenges with slowing revenue growth, heavy debt, and profitability concerns despite recent margin expansion. WALD's acquisition of Novaestiq aims to double its addressable market by entering the U.S. dermal filler space under the Obagi brand, with risk-mitigating deal terms. Recent trading updates show Milk Makeup's U.S. growth via Ulta and Amazon, while Obagi excels internationally, but overall FY 2025 guidance has been lowered. Despite a potential 20% upside to the $2.50–2.70 range, I maintain a 'Hold' rating as structural issues and dilution risks persist. Read the full article on Seeking AlphaAnaliz Makalesi • Aug 21
Waldencast plc (NASDAQ:WALD) Stocks Pounded By 26% But Not Lagging Industry On Growth Or Pricing
NasdaqCM:WALD 1 Year Share Price vs Fair Value Explore Waldencast's Fair Values from the Community and select yours The...Anlatı Güncellemesi • Aug 21
Expansion Into Ulta Beauty Stores Will Boost Future Success
The Analyst Price Target for Waldencast was reduced to $3.50 from $3.98, reflecting concerns about softer international demand, operational disruptions, strategic uncertainty, and delayed reporting, despite some positive momentum at core brands. Analyst Commentary Moderated annual outlook due to softening international consumption and out-of-stock issues at Waldencast brands.Analiz Makalesi • May 14
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Analiz Makalesi • Apr 09
It's Down 29% But Waldencast plc (NASDAQ:WALD) Could Be Riskier Than It Looks
Waldencast plc ( NASDAQ:WALD ) shareholders that were waiting for something to happen have been dealt a blow with a 29...
Yeni Anlatı • Mar 30
Expansion Into Ulta Beauty Stores Will Boost Future Success
Strong growth in Milk Makeup and Obagi Medical, with store expansion and innovation driving increased future revenue and market share.Analiz Makalesi • Aug 13
Waldencast plc (NASDAQ:WALD) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 26% in the last...Seeking Alpha • Jun 28
Waldencast Plc: Investors Continue To Demand More Growth
Summary Waldencast plc provides 'Milk Makeup' & 'Obagi' brands in beauty & wellness industry. Q1 2024 saw 21% revenue growth, improved profitability trends, and increased adjusted EBITDA for Waldencast. Fiscal 2024 guidance includes expectations of continued growth through e-commerce, international sales, and brand partnerships. Read the full article on Seeking AlphaAnaliz Makalesi • Jun 19
We Think Waldencast (NASDAQ:WALD) Has A Fair Chunk Of Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analiz Makalesi • May 11
Waldencast plc (NASDAQ:WALD) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless
To the annoyance of some shareholders, Waldencast plc ( NASDAQ:WALD ) shares are down a considerable 29% in the last...Analiz Makalesi • Apr 07
Waldencast plc's (NASDAQ:WALD) Intrinsic Value Is Potentially 55% Above Its Share Price
Key Insights Waldencast's estimated fair value is US$14.29 based on 2 Stage Free Cash Flow to Equity Waldencast's...Analiz Makalesi • Dec 14
Is Waldencast plc (NASDAQ:WALD) Trading At A 42% Discount?
How far off is Waldencast plc ( NASDAQ:WALD ) from its intrinsic value? Using the most recent financial data, we'll...Hissedar Getirileri
| WALD | US Personal Products | US Pazar | |
|---|---|---|---|
| 7D | -2.3% | 4.4% | -0.7% |
| 1Y | -35.6% | -14.4% | 20.3% |
Getiri vs. Endüstri: WALD geçen yıl % -14.4 oranında getiri sağlayan US Personal Products sektörünün gerisinde kaldı.
Getiri vs Piyasa: WALD geçen yıl % 20.3 oranında getiri sağlayan US Piyasasının altında performans gösterdi.
Fiyat Oynaklığı
| WALD volatility | |
|---|---|
| WALD Average Weekly Movement | 22.2% |
| Personal Products Industry Average Movement | 8.3% |
| Market Average Movement | 7.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: WALD hisse senedi fiyatı, son 3 ayda US piyasasına kıyasla dalgalı seyretti.
Zaman İçindeki Volatilite: WALD 'nin haftalık oynaklığı geçtiğimiz yıl boyunca 15% dan 22% a yükseldi.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| 2020 | 367 | Michel Brousset | www.waldencast.com |
Waldencast plc, Amerika Birleşik Devletleri, Kanada, Avrupa, Orta Doğu, Hindistan, Avustralya ve Yeni Zelanda'da güzellik ve sağlıklı yaşam sektöründe faaliyet göstermektedir. Şirket, Obagi Medical ve Milk Makeup olmak üzere iki segmentte faaliyet göstermektedir. Şirket, cilt yaşlanması belirtilerini en aza indirmek, koyu lekeleri, hiperpigmentasyonu, ince çizgileri ve kırışıklıkları gidermek ve cilt tonunu ve dokusunu korumak ve geliştirmek için cilt bakım ürünleri; kozmetikler; ve diğer güzellik ürünleri sunmaktadır.
Waldencast plc Temel Bilgiler Özeti
| WALD temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$215.48m |
| Kazançlar(TTM) | -US$229.75m |
| Gelir(TTM) | US$272.07m |
0.7x
P/S Oranı-0.9x
F/K OranıWALD aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| WALD gelir tablosu (TTM) | |
|---|---|
| Gelir | US$272.07m |
| Gelir Maliyeti | US$89.05m |
| Brüt Kâr | US$183.02m |
| Diğer Giderler | US$412.77m |
| Kazançlar | -US$229.75m |
Son Raporlanan Kazançlar
Dec 31, 2025
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | -1.94 |
| Brüt Marj | 67.27% |
| Net Kâr Marjı | -84.44% |
| Borç/Özkaynak Oranı | 27.3% |
WALD uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/07 06:10 |
| Gün Sonu Hisse Fiyatı | 2026/07/07 00:00 |
| Kazançlar | 2025/12/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları GitHub sayfamızda mevcuttur; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Waldencast plc 4 Bu analistlerden 3, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Aaron Grey | Alliance Global Partners |
| Susan Anderson | Canaccord Genuity |
| Jungwon Kim | TD Cowen |